Business
"Transforming at Scale" - SXSW London 2025 - Conference - Day Three
Mark Read, CEO of WPP, speaking in London, June 4, 2025 (Jeff Spicer/Getty Images)
madder men

The ad agencies are staring down the barrel of AI

WPP’s CEO is stepping down as artificial intelligence threatens some of the core functions of the agency model.

David Crowther

The world of advertising feels like one that we all know intimately, with each of us faced with an almost overwhelming bombardment of logos, promos, and ads every single day.

But how many advertising firms can you actually name? If the answer is “not many,” you’re not alone.

That’s because there are thousands of advertising agencies, each bursting with creative individuals looking to nudge our collective consciousness to be a little bit more sympathetic to the brands they’re tasked with representing on billboards, screens, and in print. Many of those agencies are owned by one of six major players that dominate the landscape — each one is having a tough 2025.

Ad Agencies
Sherwood News

The “big six,” the parent companies of dozens of smaller outlets, have all seen shares drop this year, but the largest — UK-based WPP — is hurting the most, with CEO Mark Read announcing his departure this morning, as the company’s stock has slumped by more than one-third so far this year.

Winter is coming

In the competitive world of advertising, industry execs are comfortable campaigning against each other for mandates to run all things advertising for major brands like Coca-Cola, Starbucks, and Nike. With the advent and popularization of AI, however, a new threat has emerged.

Just last week, Meta rocked the big six after The Wall Street Journal reported that the social media giant was planning to launch tools that would completely automate ad creation and targeting. That could mean the same product being shown in completely different settings to different users. For instance, an ad for a watch might show one user the timepiece on the wrist of a climber ascending to great heights, while someone else might see the same model on someone stepping out of a beautiful car, at a concert, playing a sport, or reading a newsletter on their phone.

With many other parts of the agency-brand relationship, like project management and media planning, already susceptible to AI tools, the creative part of the job was perhaps seen as one aspect that might be harder to replace. I’m not sure I’m ready for the ads on my Instagram to get any worse, but here we are.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.